From cellular receptors to transduction–transcription pathways for cytokines: at which level should the inhibition be targeted in inflammation?

Bibliography

• AGGARWAL BB, SAMANTA A, FELDMANN M: TNF receptors. In: Cytokine Reference. Oppenheim JJ, Feldmann M (Eds), London, Academic Press (2000):1619–1632.
   Google Scholar
• AGGARWAL BB, SAMANTA A, FELDMANN M: TNF-alpha. In: Cytokine Reference. Oppenheim JJ, Feldmann M (Eds.), London, Academic Press (2000):413–434.
   Google Scholar
• DINARELLO CA: Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr. Opin. Pharmacol (2004) 4:378–385.
   PubMed Web of Science ®Google Scholar
• BURGER D, DAYER JM: IL-1Ra. In: Cytokine Reference. Oppenheim JJ, Feldmann M (Eds), London, Academic Press (2000):319–336.
   Google Scholar
• COLOTTA F, DOWER SK, SIMS JE et al: The type II 'decoy receptor: a novel regulatory pathway for interleukin 1. Immunol Today(1994) 15:562–566.
   PubMedGoogle Scholar
• CHIZZOLINI C, DAYER JM: Cytokine inhibitors. In: Encyclopedia of Immunology (2nd Ed.). Delves PJ, Roitt IM (Eds), London, Academic Press (1998):702–707.
   Google Scholar
• ECONOMIDES AN, CARPENTER LR, RUDGE JS et al: Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. (2003) 9:47–52.
   PubMed Web of Science ®Google Scholar
• SECKINGER P, LOWENTHAL JW, WILLIAMSON K et al: A urine inhibitor of interleukin 1 activity that blocks ligand binding. J. Immunol (1987) 139:1546–1549.
   PubMed Web of Science ®Google Scholar
• FERRARI-LACRAZ S, ZANELLI E, NEUBERG M et al: Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J. Immunol (2004) 173:5818–5826.
   PubMed Web of Science ®Google Scholar
• ADAMS G, VESSILLIER S, DREJA H et al: Targeting cytokines to inflammation sites. Nat. Biotechnol. (2003) 21:1314–1320.
   PubMed Web of Science ®Google Scholar
• MANTOVANI A, BONECCHI R, MARTINEZ FO et al.: Tuning of innate immunity and polarized responses by decoy receptors. mt. Arch. Allergy Immunol. (2003) 132:109–115.
   PubMed Web of Science ®Google Scholar
• D'AMICO G, FRASCAROLI G, BIANCHI G et al: Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. Nat. Immunol (2000) 1:387–391.
   PubMed Web of Science ®Google Scholar
• MCFADDEN G, KELVIN D: New strategies for chemokine inhibition and modulation: you take the high road and I'll take the low road. Biochem. Pharmacol (1997) 54:1271–1280.
   PubMed Web of Science ®Google Scholar
• JOHNSON Z, KOSCO-VILBOIS MH, HERREN S et al: Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. ./. Immunol. (2004) 173:5776–5785.
   PubMed Web of Science ®Google Scholar
• STEINMAN L: Immune therapy for autoimmune diseases. Science (2004) 305:212–216.
   PubMed Web of Science ®Google Scholar
• HYKA N, DAYER JM, MODOUX C et al.: Apolipoprotein A-I inhibits the production of interleukin-lbeta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood (2001) 97:2381–2389.
   PubMed Web of Science ®Google Scholar
• BURGER D, DAYER JM: The role of human T lymphocyte-monocyte contact in inflammation and tissue destruction. Arthritis Res. (2002) 4\(Suppl. 3):5169–5176.
   Google Scholar
• DAYER JM, BURGER D: Cell-cell interactions and tissue damage in rheumatoid arthritis. Autoimmun. Rev (2004) 3\(Suppl. 1):S14–S16.
   Google Scholar
• STEINMAN L: Elaborate interactions between the immune and nervous systems. Nat. Immunol (2004) 5:575–581.
   PubMed Web of Science ®Google Scholar
• MOREL J, BERENBAUM F: Signal transduction pathways: new targets for treating rheumatoid arthritis. Joint Bone Spine (2004) 71:503–510.
   PubMed Web of Science ®Google Scholar
• ULEVITCH RJ: Therapeutics targeting theinnate immune system. Nat. Rev Immunol. (2004) 4:512–520.
   PubMed Web of Science ®Google Scholar
• KARIN M, YAMAMOTO Y, WANG QM: The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. (2004) 3:17–26.
   PubMed Web of Science ®Google Scholar
• MCINTYRE KW, SHUSTER DJ, GILLOOLY KM et al: A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum. (2003) 48:2652–2659.
   PubMed Web of Science ®Google Scholar
• HAMMAKER D, SWEENEY S, FIRESTEIN GS: Signal transduction networks in rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62\(Suppl. 2):ii86-ii89.
   Google Scholar
• AUPPERLE KR, BENNETT BL, BOYLE DL et al: NF-kappa B regulation by I kappa B kinase in primary fibroblast-like synoviocytes. Immunol (1999) 163:427–433.
   Web of Science ®Google Scholar
• ELLIOTT PJ, ZOLLNER TM, BOEHNCKE WH: Proteasome inhibition: a new anti-inflammatory strategy. I Ma. Med. (2003) 81:235–245.
   PubMed Web of Science ®Google Scholar
• ADAMS J, KAUFFMAN M: Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest. (2004) 22:304–311.
   PubMed Web of Science ®Google Scholar
• BONDESON J, FOXWELL B, BRENNAN F et al: Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc. Nati Acad. Sci. USA (1999) 96:5668–5673.
   PubMed Web of Science ®Google Scholar
• LAWRENCE T, GILROY DW, COLVILLE-NASH PR et al: Possible new role for NF-kappaB in the resolution of inflammation. Nat. Med. (2001) 7:1291–1297.
   PubMed Web of Science ®Google Scholar
• ARKIN MR, WELLS JA: Small-moleculeinhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev Drug Discov. (2004) 3:301–317.
   PubMed Web of Science ®Google Scholar
• BARTFAI T, BEHRENS MM, GAIDAROVA S et al.: A low molecular weight mimic of the Toll/IL-1 receptor/ resistance domain inhibits IL-1 receptor-mediated responses. Proc. Natl. Acad. Sci. USA (2003) 100:7971–7976.
   PubMed Web of Science ®Google Scholar
• SCHINDLER C, DARNELL JE Jr: Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Ann. Rev Biochem. (1995) 64:621–651.
   PubMed Web of Science ®Google Scholar
• PAUKKU K, SILVENNOINEN 0: STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5. Cytokine Growth Factor Rev. (2004) 15:435–455.
   PubMed Web of Science ®Google Scholar
• PFITZNER E, KLIEM S, BAUS D et al:The role of STATs in inflammation and inflammatory diseases. Curr. Pharm. Des. (2004) 10:2839–2850.
   PubMed Web of Science ®Google Scholar
• MOLNARFI N, HYKA-NOUSPIKEL N, GRUAZ L et al: The production of IL-1 receptor antagonist in IFN-13-stimulated human monocytes depends on the activation of phosphatidylinositol 3-kinase but not of STAT1. Immunol (2005) 174:2974–2980.
   Web of Science ®Google Scholar
• NAVARRO A, ANAND-APTE B, TANABE Y et al: A PI-3 kinase-dependent, Statl-independent signaling pathway regulates interferon-stimulated monocyte adhesion. J. Leukoc. Biol. (2003) 73:540–545.
   PubMed Web of Science ®Google Scholar
• NAKA T, TSUTSUI H, FUJIMOTO M et al.:SOCS- 1/SSI- 1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-gamma and IL-4 signaling in vivo. Immunity (2001) 14:535–545.
   PubMed Web of Science ®Google Scholar
• EGAN PJ, LAWLOR KE, ALEXANDER WS et al: Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. Clin. Invest (2003) 111:915–924.
   Google Scholar
• SHOUDA T, YOSHIDA T, HANADA T et al.: Induction of the cytokine signal regulator 50053/CI53 as a therapeutic strategy for treating inflammatory arthritis. Clin. Invest. (2001) 108:1781–1788.
   Google Scholar
• DALPKE AH, OPPER S, ZIMMERMANN S etal.: Suppressors of cytokine signaling (SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. Immunol (2001) 166:7082–7089.
   Google Scholar
• O'SHEA JJ, WATFORD W: A peek at PIAS. Nat. Immunol (2004) 5:875–876.
   PubMed Web of Science ®Google Scholar
• O'SHEA JJ: Targeting the Jak/STAT pathway for immunosuppression. Ann. Rheum. Dis. (2004) 63\(Suppl. 2):067–071.
   Google Scholar
• IVASHKIV LB, HU X: Signaling by STATs. Arthritis Res. Ther. (2004) 6:159–168.
   PubMed Web of Science ®Google Scholar
• MORI Y, CHEN SJ, VARGA J: Expressionand regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum. (2003) 48:1964–1978.
   PubMed Web of Science ®Google Scholar
• KULKARNI AB, HUH CG, BECKER D et al.: Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Li. USA (1993) 90:770–774.
   PubMed Web of Science ®Google Scholar
• SHULL MM, ORMSBY I, KIER AB et al: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature (1992) 359:693–699.
   PubMed Web of Science ®Google Scholar
• GORELIK L, FLAVELL RA: Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity (2000) 12:171–181.
   PubMed Web of Science ®Google Scholar
• MONTELEONE G, KUMBEROVA A, CROFT NM et al: Blocking Smad7 restores TGF-betal signaling in chronic inflammatory bowel disease. J. Clin. Invest. (2001) 108:601–609.
   PubMed Web of Science ®Google Scholar
• INMAN GJ, NICOLAS FJ, HILL CS: Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. Mol. Cell (2002) 10:283–294.
   PubMedGoogle Scholar
• DONG C, DAVIS RJ, FLAVELL RA: MAP kinases in the immune response. AMU. Rev Immunol (2002) 20:55–72.
   PubMed Web of Science ®Google Scholar
• PEARSON G, ROBINSON F, BEERS GT et al.: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev (2001) 22:153–183.
   PubMed Web of Science ®Google Scholar
• NICK JA, AVDI NJ, YOUNG SK et al.: Selective activation and functional significance of p38alpha mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils. Clin. Invest. (1999) 103:851–858.
   Google Scholar
• KARIN M: Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs. Ann. Rheum. Dis. (2004) 63\(Suppl. 2):062–064.
   Google Scholar
• ENGLISH JM, COBB MH: Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Li. (2002) 23:40–45.
   PubMed Web of Science ®Google Scholar
• SAKLATVALA J: The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr. Opin. Pharmacol (2004) 4:372–377.
   PubMed Web of Science ®Google Scholar
• TAS SW REMANS PH, REED QUIST KA et al: Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy. Curr. Pharm. Des (2005) 11:581–611.
   PubMed Web of Science ®Google Scholar
• VENTURA JJ, KENNEDY NJ, LAMB JA et al: c-Jun NH(2)-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol. Cell Biol. (2003) 23:2871–2882.
   PubMed Web of Science ®Google Scholar
• HAN Z, BOYLE DL, MANNING AM et al: AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunio, (1998) 28:197–208.
   PubMed Web of Science ®Google Scholar
• KOLLER M, HAYER S, REDLICH K et al: JNK1 is not essential for TNF-mediated joint disease. Arthritis Res. Ther. (2005) 7:R166–R173.
   Google Scholar
• WARD S, SOTSIOS Y, DOWDEN J et al: Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem. Biol. (2003) 10:207–213.
   PubMed Web of Science ®Google Scholar
• FUKAO T, KOYASU S: PI3K and negative regulation of TLR signaling. Trends Immunol (2003) 24:358–363.
   PubMed Web of Science ®Google Scholar
• CANTLEY LC: The phosphoinositide 3-kinase pathway. Science (2002) 296: 1655-1657.
   Google Scholar
• REDDY SA, HUANG JH, LIAO WS: Phosphatidylinositol 3-kinase in interleukin 1 signaling. Physical interaction with the interleukin 1 receptor and requirement in NFkappaB and AP-1 activation. Biol. Chem. (1997) 272:29167–29173.
   Google Scholar
• CONEJO R, DE ALVARO C, BENITO Met al: Insulin restores differentiation of Ras-transformed C2C12 myoblasts by inducing NF-kappaB through an AKT/P7056K/p38-MAPK pathway. Oncogene (2002) 21:3739–3753.
   PubMed Web of Science ®Google Scholar
• FRUMAN DA, CANTLEY LC: Phosphoinositide 3-kinase in immunological systems. Semin. Immunol (2002) 14:7–18.
   PubMed Web of Science ®Google Scholar
• MOREL JC, PARK CC, ZHU K et al: Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J. Biol. Chem. (2002) 277:34679-34691. Expert Op/n. Biol. Ther. (2005) 5\(Supp1.1)
   Google Scholar
• MOREL JC, PARK CC, WOODS JM et al: A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. I Biol. Chem. (2001) 276:37069–37075.
   Web of Science ®Google Scholar
• BRENNAN FM, HAYES AL, CIESIELSKI CJ et al: Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. Arthritis Rheum. (2002) 46:31–41.
   PubMed Web of Science ®Google Scholar
• BURGER D, MOLNARFI N, GRUAZ L et al: P13-K is a checkpoint in the production of interleukin-1 beta (IL-1 beta) and IL-1 receptor antagonist. Eur. Biochem. (2002) 269\(Suppl. 0:106.
   Google Scholar
• FOEY AD, GREEN P, FOX WELL B et al: Cytokine-stimulated T cells induce macrophage IL-10 production dependent on phosphatidylinositol 3-kinase and p7056K: implications for rheumatoid arthritis. Arthritis Res. (2002) 4:64–70.
   PubMedGoogle Scholar
• OKKENHAUG K, BILANCIO A, FARJOT G et al: Impaired B and T cell antigen receptor signaling in p 1 10delta PI 3- kinase mutant mice. Science (2002) 297:1031–1034.
   PubMed Web of Science ®Google Scholar
• DI CRISTOFANO A, PANDOLFI PP: The multiple roles of PTEN in tumor suppression. Cell (2000) 100:387–390.
   PubMed Web of Science ®Google Scholar
• KOUL D, YAO Y, ABBRUZZESE JL et al:Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway../. Biol. Chem. (2001) 276:11402–11408.
   PubMed Web of Science ®Google Scholar
• PAP T, FRANZ JK, HUMMEL KM et al: Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res. (2000) 2:59–64.
   PubMedGoogle Scholar
• FANG H, PENGAL RA, CAO X et al: Lipopolysaccharide-induced macrophage inflammatory response is regulated by SHIP. ffinmunol. (2004) 173:360–366.
   Google Scholar
• ONODERA S, NISHIHIRA J, KOYAMA Y et al.: Macrophage migration inhibitory factor up-regulates the expression of interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid arthritis patients: common transcriptional regulatory mechanism between interleukin-8 and interleukin- 1 beta. Arthritis Rheum. (2004) 50:1437–1447.
   PubMed Web of Science ®Google Scholar
• WANG K, SCHEEL-TOELLNER D, WONG SH et al.: Inhibition of neutrophil apoptosis by type 1 IFN depends on cross-talk between phosphoinositol 3-kinase, protein kinase C-delta, and NF-kappaB signaling pathways. J. Immunol (2003) 171:1035–1041.
   PubMed Web of Science ®Google Scholar
• TEIXEIRA MM, GRISTWOOD RW, COOPER N et al: Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol ScL (1997) 18:164–171.
   PubMed Web of Science ®Google Scholar
• MEISEL C, VOGT K, PLATZER C et al:Differential regulation of monocytic tumor necrosis factor-alpha and interleukin-10 expression. Eur. I Immunol (1996) 26:1580–1586.
   PubMed Web of Science ®Google Scholar
• ROSS SE, WILLIAMS RO, MASON LJ et al.: Suppression of TNF-alpha expression, inhibition of Thl activity, and amelioration of collagen-induced arthritis by rolipram. Immunol (1997) 159:6253–6259.
   Web of Science ®Google Scholar
• MARX N, MACKMAN N, SCHONBECK U et al: PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation (2001) 103:213–219.
   PubMed Web of Science ®Google Scholar
• DELERIVE P, DE BOSSCHER K, BESNARD S et al: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Bial Chem. (1999) 274:32048–32054.
   PubMed Web of Science ®Google Scholar
• KOTA BP, HUANG TH, ROUFOGALIS BD: An overview on biological mechanisms of PPARs. Pharmacol Res. (2005) 51:85–94.
   PubMed Web of Science ®Google Scholar
• SHU H, WONG B, ZHOU G et al: Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem. Biophys. Res. Commun. (2000) 267:345–349.
   PubMed Web of Science ®Google Scholar
• URNOV FD, WOLFFE AP: Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene (2001) 20:2991–3006.
   PubMed Web of Science ®Google Scholar
• CHUNG YL, LEE MY, WANG AJ et al: A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Then (2003) 8:707–717.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN JL, BROWN MS: Regulation of the mevalonate pathway. Nature (1990) 343:425–430.
   PubMed Web of Science ®Google Scholar
• KWAK B, MULHAUPT F, MYIT S et al:Statins as a newly recognized type of immunomodulator. Nat. Med. (2000) 6:1399–1402.
   PubMed Web of Science ®Google Scholar
• YOUSSEF S, STUVE 0, PATARROYO JC et al: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (2002) 420:78–84.
   PubMed Web of Science ®Google Scholar
• STEINMAN L: Immunotherapy of multiple sclerosis: the end of the beginning. Curt: Opin. Immunol (2001) 13:597–600.
   PubMed Web of Science ®Google Scholar
• PALMER G, CHOBAZ V, TALABOT-AYER D et al: Assessment of the efficacy of different statins in murine collagen-induced arthritis. Arthritis Rheum. (2004) 50:4051–4059.
   PubMed Web of Science ®Google Scholar
• VOLLMER T, KEY L, DURKALSKI V et al: Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet (2004) 363:1607–1608.
   PubMed Web of Science ®Google Scholar
• MCCAREY DW, MCINNES IB, MADHOK R et al: Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 363:2015–2021.
   PubMed Web of Science ®Google Scholar
• HALLORAN PF: Immunosuppressive drugs for kidney transplantation. N Engl. Med. (2004) 351:2715–2729.
   PubMed Web of Science ®Google Scholar
• DORSETT Y, TUSCHL T: siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev Drug Discov. (2004) 3:318–329.
   PubMed Web of Science ®Google Scholar
• CRINELLI R, BIANCHI M, GENTILINI L et al.: Transcription factor decoy oligonucleotides modified with locked nucleic acids: an in vitro study to reconcile biostability with binding affinity. Nucleic Acids Res. (2004) 32:1874–1885.
   PubMed Web of Science ®Google Scholar
• MAGNANI M, ROSSI L, FRATERNALE et al: Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther. (2002) 9:749–751.
   PubMed Web of Science ®Google Scholar
• VAN DE LOO FA: Inflammation-responsive promoters for fine-tuned gene therapy in rheumatoid arthritis. Curr. Opia Mol Ther. (2004) 6:537–545.
   PubMed Web of Science ®Google Scholar
• BUGELSKI PJ: Genetic aspects of immune-mediated adverse drug effects. Nat. Rev Drug Disco v. (2005) 4:59–69.
   PubMed Web of Science ®Google Scholar